Research

Dr. Gordon is involved in multiple clinical trials that allow her to offer cutting edge treatment to her patients in a study atmosphere. Currently Dr. Gordon is involved in multiple studies including those that target new treatments in diabetic retinopathy, macular degeneration, retinal vein occlusion and uveitis. We are very honored to participate in these studies and are excited about the contribution they will make to future treatments in ophthalmology and patient care.

For a complete list of clinical trials in your area visit http://www.clinicaltrials.gov.

• Principal Investigator
  VGFT-OD-0605 (VIEW I) Phase III Randomized, Double Masked, Active Controlled Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (December 2007- 2011)
  Sponsor: Regeneron Pharmaceuticals
• Principal Investigator
  EOP 1023 (LEVEL Trial) Phase IV Induction Maintenance trial using Avastin or Lucentis combined with Macugen for treatment of Exudative AMD (May 2007 - August 2008)
  Sponsor: OSI/Eyetech
• Principal Investigator
  VGFT-OD-0706 (DA VINCI) Phase II Double Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (December 2008 - January 2011)
  Sponsor: Regeneron Pharmaceuticals
• Principal Investigator
  VGFT-OD-0819 (COPERNICUS) Phase II Randomized, Double Masked, Controlled Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) (July 2009 – 2012)
  Sponsor: Regeneron Pharmaceuticals
• Principal Investigator
  C-09-023 (WALTZ) Phase II Dose-Escalation Study of AL-39324 Suspension versus Lucentis® for the Treatment of Exudative Age-Related Macular Degeneration (November 2009 - May 2011)
  Sponsor: Alcon
• Principal Investigator
  FVF4679g (HARBOR) Phase III, double-masked, multicenter randomized, active treatment-controlled study of the efficacy and safety of 0.5mg and 2.0mg Ranibizumab administered monthly or on an as-needed bases (PRN) in patients with subfoveal neovascular age-related macular degeneration (¬February 2010 – 2012)
  Sponsor: Genentech
• Principal Investigator
  C-09-067 (RACE) Phase IIA Controlled, Double Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD (September 2010 – 2011)
  Sponsor: Alcon
• Sub-Investigator
  32-007 (SAKURA) Phase III multinational, multicenter, randomized, double-masked, study assessing the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution for the treatment of non infectious uveitis. (June 2011 – 2013)
  Sponsor: Santen, Inc.
• Principal Investigator
  VGFT-OD-1009 (VISTA) Phase III double-masked, randomized, active-controlled, study of the efficacy and safety of intravitreal administration of VEGF Trap-Eye in patients with Diabetic Macular Edema (July 2011-present)
  Sponsor: Regeneron
• Principal Investigator
  ¬FVF4967g (SHORE) Phase IV multicenter randomized study evaluation dosing regimens for treatment with intravitreal ranibizumab injections in subjects with macular edema following retinal vein occlusion (March 2011 – April 2013)
  Sponsor: Genentech
• Sub Investigator
  2010-007-03- DME (iDEAL) Phase II study of the safety, tolerability., and bioactivity of repeated intravitreal injections of iC)-007 as monotherapy or in combination with ranibizumab or laser photocoagulation in the treatment of diabetic macular edema (February 2012- October 2013)
  Sponsor: Juvenile Diabetes Research Foundation International
• Principal Investigator
  VGFTe-RVO-1027 ( VIBRANT) Phase III double masked, randomized, active-controlled study of the efficacy, safety, and tolerability of intravitreal administration of VEGF Trap-eye (intravitreal Afibercept injection [IAI]) in patients with macular edema secondary to Branch Retinal Vein Occlusion. (April 2012 – present)
  Sponsor: Regeneron
• Principal Investigator
  C-12-006 ¬(OSPREY¬) Phase II Prospective, randomized, double masked, multi-center, two armed study comparing the efficacy and safety of ESBA 1008 versus Eylea ® in subjects with exudative age related macular degeneration. ¬(March 2913 – present)
  Sponsor: ALCON
• Principal Investigator
  X052131/CL3-78989-005¬ (XOMA) Phase III study of safety and efficacy of Gevokizumab to treat active non infectious uveitis. (March 2013 – present)
  Sponsor: Janix
• Principal Investigator
  Novartis CLFG316A 2203 Phase II multi-center, randomized, sham control, proof of concept, study of patients with with geographic atrophy associated with age related macular degeneration, using intravitreal LFG316 . (January 2012 – present)
  Sponsor: Novartis
• Principal Investigator
  L-Path LT 1009/(iSONEP ™ NEXUS) Phase 2a, multicenter, masked, randomized, comparator- controlled study evaluation iSONEP ™ as either monotherapy or adjunctive therapy to Lucentis ® or Avastin® versus Lucentis ® or Avastin® alone for the treatment of subjects with choroidal neovascularization secondary to age related macular degeneration. (August 2012 – present)
  Sponsor: L-Path, Inc.
• Principal Investigator
  AP-05-002 Phase II Randomized, Placebo Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina™ in Adult Patients with Diabetic Macular Edema (August 2013-present)
  Sponsor: Ampio Pharmaceuticals, Inc.
• Principal Investigator
  VGFTe-AMD-1124.02 (REVIEW) Phase IV Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration. (September-present)
  Sponsor: Regeneron Pharmaceuticals, Inc.
• Principal Investigator
  OPH1002 / PXL#212164 Phase 3 randomized, double-masked, control trial to establish the safety and efficacy of intravitreous administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age related macular degeneration. (October-present)
  Sponsor: Ophthotech